The Financial Express2 天
THIS diabetes medication can also reduce risk of heart attack and stroke, Lancet study reveals
While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...
Breakthrough medication significantly cuts risk of heart attacks and strokes: Lancet study
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
Medical News Today3 天
Drug for diabetes and kidney disease may also lower heart attack, stroke risks
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...
Healio5 天
Rising diabetes prevalence in low-income countries ‘alarming and discouraging’
The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...
Daily2 天
Sotagliflozin significantly lowers Heart Attack and Stroke Risk, reports Lancet study
Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...
The Lancet1 天
Vitamin D and acute respiratory infections: a definitive answer?
Acute respiratory infections (ARIs) are a common cause of illness in children younger than 16 years and adults older than 65 ...
The Lancet3 天
Time to reframe the disease staging system for type 1 diabetes
aDepartment of Paediatrics and Department of Pathology, Immunology and Laboratory Medicine, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL, USA ...
New FDA-Approved Diabetes Drug Slashes Heart Attack and Stroke Risk
Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...